After its potential kidney disease drug went down in flames late last year, Novo Nordisk is pinning the blame on alleged fraudulent claims by the drug’s original maker. | After its potential kidney ...

Novo Nordisk has announced plans to move its ziltivekimab into phase 3 clinical development in atherosclerosis with chronic kidney disease after a mid-stage trial met its main goal.

The FDA’s recent approval of OZEMPIC highlights the expanding use of GLP-1 drugs beyond diabetes and weight management. Novo Nordisk’s blockbuster medication has gained another label expansion, now ...

In this regard Novo Nordisk is leading the way. We've become increasingly committed to chronic conditions that include cardiovascular disease and chronic kidney disease – the reason being ...

EXTON, PA, Feb. 05, 2025 (GLOBE NEWSWIRE) -- As chronic kidney disease (CKD ... following the FDA’s recent label expansion of Novo Nordisk’s Ozempic® to include CKD benefits, reinforcing ...

Novo Nordisk’s cannabinoid CB1 receptor blocker ... the Danish drugmaker has reported the failure of a midphase diabetic kidney disease trial of the molecule. CB1 receptor blockade is an old ...

A drug that Novo Nordisk acquired to expand its prospects in metabolic disorders has failed a mid-stage clinical trial in diabetic kidney disease. The results also showed signs of a ...

Novo Nordisk launched "My Ozempic® Era" today, a national campaign which spotlights the longstanding Ozempic® patient ...

Novo Nordisk responded ... adults with T2D and established CV disease, and to reduce the sustained estimated glomerular filtration rate (eGFR) decline, end-stage kidney disease, and CV death in adults ...

Novo Nordisk's blockbuster medication has gained another label expansion, now authorized for treating chronic kidney disease. New York, USA, Feb. 19, 2025 (GLOBE NEWSWIRE) -- Novo Nordisk's ...